Real-world study of secukinumab for HS in Canada
Part of Infections, Skin clinical trials.
This study looks at how well secukinumab (Cosentyx) works in real life for people with moderate-to-severe hidradenitis suppurativa (HS) in Canada. If you're just starting this treatment, researchers want to track your progress and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older) diagnosed with moderate-to-severe hidradenitis suppurativa (HS).
- You are starting secukinumab (Cosentyx) for the first time, or started it within the last 7 days.
- You have not taken secukinumab before (for more than a week).
- You can understand and give consent in Canadian English or French.
- You have no medical conditions or allergies that would make secukinumab unsafe for you (as decided by your doctor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how secukinumab (a new medication) works for hidradenitis suppurativa—a painful skin condition with recurring boils and abscesses—in real-world patient care in Italy. Researchers want to understand treatment patterns and outcomes to help improve care for this condition.
This study looks at how well secukinumab works when started early for people with moderate to severe hidradenitis suppurativa (HS). It aims to understand if early treatment can improve symptoms and reduce the need for surgery.
This study looks at how secukinumab affects heart health in people with moderate-to-severe hidradenitis suppurativa (HS) who also have high cardiovascular risk or existing plaque in their heart arteries. It aims to see if this treatment might help both their skin and heart.
This trial tests two medications, secukinumab and tofacitinib, to see which works better for moderate to severe hidradenitis suppurativa (a skin condition causing painful bumps) in Chinese patients. The goal is to find a more effective treatment option.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This study tracks how well Cosentyx works in real-world use for people with hidradenitis suppurativa, plaque psoriasis, or juvenile idiopathic arthritis. It helps doctors understand the medicine's long-term effects in Korean patients.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.